Four insights:
1. Royal Biologics develops biologics, orthobiologics and orthopedic implants used in stem cells and other surgical procedures.
2. This is the first healthcare investment of Granite Creek’s recently closed $200 million FlexCap II fund.
3. The investment will be used to expedite new hires, expand operations, increase product development and pursue acquisitions.
4. Two partners at Granite Creek — Jim Clark and Mark Radzik — will serve on the board of Royal Biologics.
More articles on biologics:
Ortho RTi unveils new CEO — 4 quick insights
Minnesota seeks to expand stem cell research through state initiative — 4 insights
Stem cell controversies — Where we are in 2019
